Patents by Inventor Doran R. Pace, III

Doran R. Pace, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monoclonal antibodies to transforming growth factor-beta and methods of use
    Patent number: 6419928
    Abstract: Monoclonal antibodies to transforming growth factor beta (TGF-B) are prepared from hybrid cell lines by immunizing with TGF-B2. The antibodies may be of any isotype and may be of any mammalian origin such as murine or human origin. Therapeutic applications utilizing the TGF-B monoclonal antibody are also disclosed.
    Type: Grant
    Filed: March 21, 2000
    Date of Patent: July 16, 2002
    Assignee: Genzyme Corporation
    Inventors: James R. Dasch, Doran R. Pace, III, Wendy O. Waegell
  • Monoclonal antibodies to transforming growth factor-.beta. and methods of use
    Patent number: 6090383
    Abstract: Monoclonal antibodies to transforming growth factor beta (TGF-B) are prepared from hybrid cell lines by immunizing with TGF-B2. The antibodies may be of any isotype and may be of any mammalian origin such as murine or human origin. Therapeutic applications utilizing the TGF-B monoclonal antibody are also disclosed.
    Type: Grant
    Filed: June 15, 1998
    Date of Patent: July 18, 2000
    Inventors: James R. Dasch, Doran R. Pace, III, Wendy O. Waegell
  • Monoclonal antibodies to transforming growth factor-beta and methods of use
    Patent number: 5783185
    Abstract: Monoclonal antibodies to transforming growth factor beta (TGF-B) are prepared from hybrid cell lines by immunizing with TGF-B2. The antibodies may be of any isotype and may be of any mammalian origin such as murine or human origin. Therapeutic applications for treating or reducing the likelihood of developing acute or chronic fibrosis utilizing the TGF-B monoclonal antibody are also disclosed.
    Type: Grant
    Filed: May 4, 1995
    Date of Patent: July 21, 1998
    Assignee: Celtrix Pharmaceuticals, Inc.
    Inventors: James R. Dasch, Doran R. Pace, III, Wendy O. Waegell
  • Monoclonal antibodies to transforming growth factor-beta and methods of use
    Patent number: 5772998
    Abstract: Monoclonal antibodies to transforming growth factor beta (TGF-B) are prepared from hybrid cell lines by immunizing with TGF-B2. The antibodies may be of any isotype and may be of any mammalian origin such as murine or human origin. Therapeutic applications utilizing the TGF-B monoclonal antibody are also disclosed.
    Type: Grant
    Filed: May 4, 1995
    Date of Patent: June 30, 1998
    Assignee: Celtrix Pharmaceuticals, Inc.
    Inventors: James R. Dasch, Doran R. Pace, III, Wendy O. Waegell
  • Monoclonal antibodies which bind both transforming growth factors .beta.1 and .beta.2 and methods of use
    Patent number: 5571714
    Abstract: Monoclonal antibodies have been produced which bind to Transforming Growth Factors .beta.1 (TGF-.beta.1) and .beta.2 (TGF-.beta.2). The monoclonal antibody produced by the hybridoma designated 1D11.16 deposited as A.T.C.C. Accession No. HB 9849 binds to both TGF-.beta.1 and TGF-.beta.2. The antibodies are produced by immunizing with TGF-.beta.2 and may be of any isotype. The antibodies may be of any mammalian origin such as murine or human origin. Diagnostic and therapeutic applications utilizing the monoclonal antibodies are also disclosed.
    Type: Grant
    Filed: September 6, 1991
    Date of Patent: November 5, 1996
    Assignee: Celtrix Pharmaceuticals, Inc.
    Inventors: James R. Dasch, Doran R. Pace, III, Wendy O. Waegell